‘New GSK’ shows strength amid investor pressure, but Shingrix still needs to regain its footing
As activist investor Elliott Management turns up the heat on GlaxoSmithKline, CEO Emma Walmsley’s new vision for the company is showing strength. But while Glaxo’s va...
Continue Reading →
